JPX : 3034.T
-$14 (-0.67%)
JPX
Takashi Nakamura
Medical - Pharmaceuticals
Healthcare
3034.T
6247
JP
JPY
0.65
0.78
0.65
0.28
0.00
$290.77B
0.27
1.36
0.00
0.00
$197.32
$7.41B
2.55%
4.95%
13.50%
4.69%
10.54
0.24
0.24
4/5
0 Analysts
%
2.93
5/9
-$16.86B
$158.12B
$98.27B
$15.02B
No key metrics data available.
| Name | Title |
|---|---|
| Takayoshi Ishii | Chief of Corporate Strategy Headquarters and Senior Executive & Representative Director |
| Shinobu Karasawa | Chief of Pharmacy Business Headquarters & Executive Director |
| Kei Imai | Chief of Corporate Planning Headquarters & Director |
| Jun Kawaguchi | Chief of Gen Afrs & Disaster Countermeasures HQ, GM of Gen & Legal Afrs Dept and Director |
| Yuji Suzuki | Deputy Chief of Pharmacy Business Headquarters |
| Kiyonobu Fukumitsu | Representative, Chief of Business Management Headquarters & Executive Director |
| Yutaka Togashi | Chief of Human Resources & Education Headquarters and Executive Director |
| Takashi Nakamura | President & Representative Director |
No votes yet today — be the first to share your view!
About Qol Holdings Co., Ltd. (JPX:3034.T) Stock
Headquartered in Tokyo, Japan, Qol Holdings Co., Ltd., established in 1992, operates a diverse portfolio of businesses, primarily focusing on dispensing pharmacies and business process outsourcing (BPO) within the healthcare sector. The company establishes its dispensing pharmacies through tailored, trust-based relationships with individual medical institutions. Beyond its pharmacy operations, Qol Holdings provides extensive BPO services, including conducting sales and marketing research for pharmaceutical companies. It also specializes in dispatching temporary staff across various medical professions, such as pharmacists, nurses, registered sellers, and dietitians. Additionally, the company offers comprehensive support for clinical trials involving both pharmaceuticals and food products. ... This support encompasses a broad spectrum of services, from assisting with trial execution planning and monitoring to providing secretariat support, statistical analysis, and facilitating the presentation of conference papers, often through the dispatch of skilled managers and technicians. The company further extends its offerings to include publishing-related services. Originally named Qol Co., Ltd., the company adopted its current name, Qol Holdings Co., Ltd., in October 2018.
Frequently Asked Questions
What is the current Qol Holdings Co., Ltd. (3034.T) stock price?
Qol Holdings Co., Ltd.(JPX:3034.T) stock price is $2080 in the last trading session. During the trading session, 3034.T stock reached the peak price of $2404 while $1681 was the lowest point it dropped to. The percentage change in 3034.T stock occurred in the recent session was --0.67% while the dollar amount for the price change in 3034.T stock was -$14.
3034.T's industry and sector of operation?
The JPX listed 3034.T is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
Who are the executives of 3034.T?
Takayoshi Ishii
| Chief of Corporate Strategy Headquarters and Senior Executive & Representative Director
Shinobu Karasawa
| Chief of Pharmacy Business Headquarters & Executive Director
Kei Imai
| Chief of Corporate Planning Headquarters & Director
Jun Kawaguchi
| Chief of Gen Afrs & Disaster Countermeasures HQ, GM of Gen & Legal Afrs Dept and Director
Yuji Suzuki
| Deputy Chief of Pharmacy Business Headquarters
How many employees does 3034.T have?
Number of 3034.T employees currently stands at 6247. 3034.T operates from Shiroyama Trust Tower, Tokyo, TY 105-8452, JP.
Link for 3034.T official website?
Official Website of 3034.T is: https://www.qolhd.co.jp
How do I contact 3034.T?
3034.T could be contacted at phone #81 3 5405 9011 and can also be accessed through its website. 3034.T operates from Shiroyama Trust Tower, Tokyo, TY 105-8452, JP.
How many shares of 3034.T are traded daily?
The average number of 3034.T shares traded daily for last 3 months was 159.57K.
What is the market cap of 3034.T currently?
The market value of 3034.T currently stands at $78.16B with its latest stock price at $2080